Mural Oncology plc MURAV 深 滬
已收盤 11-15 16:00:00 美东时间
150.00
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 150.00
- 總市值 0
- 52周最高 150.00
- 市盈率 靜 --
- 換手率 NaN.00%
- 52周最低 0.00
- 委 比 0.00%
- 總股本 --
- 歷史最高 150.00
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.00
- 每 手 1
- 風險率 65.49%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Mural Oncology Announces Sanction of the Scheme by the High Court
Mural Oncology plc has announced that the High Court of Ireland has approved a scheme of arrangement under the Companies Act 2014. This scheme allows XRA 5 Corp., a subsidiary of XOMA Royalty Corporation, to acquire 100% of Mural's shares. The acquisition is expected to become effective on December 5, 2025, after the court order is delivered to the Irish Registrar of Companies. Consequently, trading of Mural shares on Nasdaq will cease on Decembe...
12-03 21:30
Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty
WALTHAM, Mass. and DUBLIN, Ireland – Mural Oncology plc shareholders approved the acquisition by XRA 5 Corp., with over 99% of votes cast in favor at both the Scheme Meeting and Extraordinary General Meeting. Under the transaction, each Mural shareholder will receive a base cash price of $2.035 per share, with an additional potential $0.205 per share based on Closing Net Cash. The acquisition, valued at approximately $36.2 million, is expected to...
10-24 20:25
Mural Oncology Announces Commencement of Mailing of Definitive Proxy Statement and Details of Scheme Meeting and Extraordinary General Meeting
Mural Oncology announced the publication of its definitive proxy statement for shareholders regarding the acquisition by XOMA Royalty, which will be voted on at the Scheme Meeting and Extraordinary General Meeting on October 24, 2025, in Dublin. The proxy statement includes details of the acquisition terms, voting instructions, and the treatment of equity awards under the Irish Takeover Rules. Shareholders are urged to review the proxy statement,...
09-23 23:52
Mural Oncology Shares Surge As Company Explores Strategic Alternatives: What's Going On?
Shares of Mural Oncology plc (NASDAQ: MURA) are soaring Monday following the company's announcement that it will discontinue clinical development of its lead drug candidate Nemvaleukin and begin exploring strategic alternatives.
04-16 02:09
Mural Oncology's Ovarian Cancer Combo Drug Trial Disappoints, Stock Plunges
Mural Oncology ends nemvaleukin development for ovarian cancer after ARTISTRY-7 trial misses survival goals. Phase 2 trials for melanoma continue into 2025.
03-25 21:28
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass and DUBLIN, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc ...
2024-12-04 05:16
Mural Oncology Appoints New Director and Audit Chair
Mural Oncology Plc ( ($MURA) ) has shared an announcement. Mural Oncology plc h...
2024-09-23 19:28
Mural Oncology Welcomes George Golumbeski as Director
Mural Oncology Plc (MURA) has provided an announcement. Mural Oncology plc anno...
2024-07-31 19:47
Mural Oncology plc GAAP EPS of -$3.57
Mural Oncology plc press release (NASDAQ:MURA): Q4 GAAP EPS of -$3.57. cash and cash equivalents were $270.9 million. More on Mural Oncology plc Recent Spin Mural Oncology At An Attractive Discount T...
2024-03-26 22:21
Mural Oncology Announces Enhancements to Late-Stage Clinical Trials
Strategic changes to ARTISTRY-6 and ARTISTRY-7, both potentially registrational...
2024-01-08 08:00
